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 Early Detection of Alzheimer's - A Crucial Requirement 
Brain is the central part of the human nervous system and any 
abnormality caused by any disease can lead to complete failure of 
human structural function. Alzheimer, an old age disease of people over 
65 years [1] causes problems with memory, thinking and behavior. This 
disease progresses very slow and its identification in early stages is 
very difficult. It is not a specific disease and the patients may have 
problems with memory, communication, concentrated attention, 
reasoning, judgment, focusing, and visual perception. The symptoms 
appear slowly and these gradually will have worse effects. In its early 
stages, not only the patients themselves but their loved ones are 
generally unable to accept that the patient is suffering from disease.  
Alzheimer’s patients forget the recent information and face 
challenges in simple arithmetic. They also have problems in speaking 
and writing, misplace things and have difficulty in retracing. Their 
interest in job and social events lessens and their mood becomes 
unpredictable. One can observe visible changes in the personality of 
the patients. On average patients live of eight years after identification 
of Alzheimer, but patients survive from 4 to 20 years depending on their 
age and other health conditions [2].  
In United States, Alzheimer's is ranked sixth disease in causing 
death and 5th for those patients who have 65 years of age and more 
[3].  During 2000 and 2008, 66 percent increase in deaths due to 
Alzheimer's has been seen, whereas the deaths from heart disease 
(ranked number one cause of death) have decreased [4].  Presently, 
in US number of Alzheimer’s patients is over 5 million. One third 
senior citizens of US die with this disease.   By 2050, the number of 
patients is expected 11 to 16 million, whereas a new patient in every 
33 seconds and one million new patients are expected every year [4].  
In 2013, expected cost caused to US is $203 billion which may rise to 
$1.2 trillion by 2050. Dr. Francis Collins, Director National Institutes of 
Health, US has designated $40 million from his fiscal year 2013 
director's budget for Alzheimer's research.  Collins also pointed out 
that President Barack Obama's FY14 budget would add $80 million 
for Alzheimer's research "over and above what's being supported” 
reflecting the way US administration prioritizes this disease. 
In 1906, German psychiatrist and neuropathologist Alois 
Alzheimer described it first time in 1906 [5]. Exact cause of Alzheimer’s 
is still to be known. Generally, it is caused due to loss 
of neurons and synapses in the cerebral cortex. Certain sub-cortical 
regions cause degeneration in the temporal lobe and parietal lobe, and 
parts of the frontal cortex [6]. Degeneration is also present in brainstem 
nuclei like the locus coeruleus [7].  MRI [Magnetic Resonance Images] 
and PET [Positron Emission Tomography] images are being used to 
determine the degeneration and reductions in the size of specific brain 
regions in people with Alzheimer’s and comparing it with healthy people 
of their age [8]. Biomarkers on MRIs and images with PET provide 
reliable information in identifying the patients’ stages of disease. Early 
detection of Alzheimer’s and its stages is very important, because as it 
worsens it has no cure and patients have very dreadful life before their 
death.  
 
Courtesy: http://science.howstuffworks.com 
Detection of Alzheimer’s is very difficult in first four stages. In 
Stage1 and Stage 2, the patient does not experience any memory 
problems, whereas in Stage 3 mild cognitive decline can be diagnosed 
in some cases. In Stage 4, some visible changes like forgetting recent 
events and problems in management of financial events are seen in the 
patients. In Stage 5, the patients have moderately severe cognitive 
decline and need help in performing routine tasks. In Stage 5, the 
patients have severe cognitive decline and have awareness problems. 
In Stage 6, they forget their personal history. In Stage 7, the patients 
have serious problems. At this stage, they need greater help in 
performing routine tasks like eating or using the toilet. They cannot sit 
without support and have difficulty in holding their heads up. They 
develop abnormal reflexes and even have a difficulty to smile [2]. It is 
very important to note that Alzheimer’s patients may face fatal 
outcomes along with non-fatal consequences like stroke, congestive 
heart failure, and ischemic attacks as a result of side effects of their 
treatment.     
Detection of the Alzheimer's is done by clinical, 
neuropsychological, and neuro-imaging assessments. Atrophy 
calculation is an effective approach at late stages of the disease. The 
pathologic hallmarks of the disease are beta-amyloid (Aß) plaques, 
neurofibrillary tangles (NFTs), and reactive gliosis [9]. Researchers are 
making efforts for early detection of Alzheimer’s, its cure or at least slow 
it down. Biomarkers in neuro-imaging provide an acceptable level of 
assistance in detection of disease and help in excluding other causes of 
dementia. Ashraf Awan et al [10] have proposed an image processing 
technique to identify brain abnormalities. They calculate the black and 
white pixels and compare these to identify the abnormalities. 
Y. Liu et al [11] have presented an approach to discover 
biomarkers to predict Alzheimer’s Dementia by using MRIs. This 
method is noninvasive and biomarkers are set to differentiate gray and 
white matter parenchyma and cerebrospinal fluid (CSF) filled spaces of 
the brain. It works in four steps: Image alignment using intensity 
normalization, midsagittal plane extraction, and affine transformation; 
feature extraction; feature screening; and subspace biomarker learning 
and cross validation using 40-fold leave ten out cross validation. The 
experiment was performed on a cluster containing 13 PCs, which had 
2.4 GHz processors, 1 GB dual channel memory, and 80 GB hard drive 
that took 7 hours to register MRIs and 25 hours for feature generation. It 
gives encouraging results (over 90% accuracy) to set biomarkers for 
image classification.  
AmirEhsan Lashkari [12] has used neural network, a feature 
selection method to classify the brain tissues. This method clearly 
describes normal and abnormal brain tissues using Gabor wavelets. 
This method saves the radiologist time, increases accuracy and yield of 
diagnosis. He has also reduced the feature space. MR images that 
have been used by him are T1_weighted, T2_weighted and PD images. 
T1_weighted MR Images shows the hard tissue darker gray scale 
density than neighbor tissues and in T2_weighted and PD, MR images 
the hard tissue is brighter gray scale density than neighbor tissues but 
in all MR images modalities, the normal tissues are almost similarity 
gray scale density.  
The proposed method estimates defiant structures with the help of 
neural network and some statistical functions, in the first step.  These 
structures are considered to be potential places that may have tumor. In 
second step, a combination of Gabor wavelets and neural network is 
used to confirm the presence of tumor or otherwise. Finally, tumor 
location and volume are computed. It is a better method as compared to 
traditional manual methods to detect the presence of abnormality in the 
human brain. It is a noninvasive procedure and in some cases it may 
predict false abnormality.   
Ramaswamy Reddy et al [13] have proposed Spatial FCM (Fuzzy 
C-means) to classify the similar data points into clusters of feature 
space.  The advantage of this method is that it allows pixels to be in 
multiple classes as compared to the traditional classification techniques 
which place each pixel in a specific class. In this algorithm, the 
probability of belonging of a pixel to specific cluster depends on the 
distance of the pixel to the centre of the cluster in the feature domain. 
This method has produced better results than K and C means 
algorithm. 
 
• Proposed Methodology 
• Resizing of all MRIs (to be analyzed) to bring them at same 
size using Interpolation Methods 
• Registration of MRIs using Biomarkers as Control Points 
• Comparing the size of the Target MRI (MRI of the potential 
Alzheimer’s Patient) with MRI of a normal person of the 
same age 
• Identification of the Target Area (part of brain to be 
analyzed) 
• Identification of Black (Cavity) and White (not Black) cells 
• Calculating the pixel values of the Black and White Arrays 
• Analysis of the Target MRI using Statistical Methods 
• Report Generation 
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